Fredun Pharmaceuticals Limited has announced the development of a new manufacturing unit in Palghar, marking the addition of its fifth production facility. This step reflects the company’s ongoing efforts to strengthen its manufacturing base and support future growth across key healthcare segments.
The upcoming facility will span approximately 40,000 square feet and is scheduled to become operational by October 2026. In addition, the company has outlined plans for a further 50,000 square feet expansion as part of its long-term growth strategy. The new unit will focus on the production of veterinary products, nutraceuticals, and pharmaceutical formulations, aligning with Fredun’s diversified portfolio.
The expansion is expected to enhance operational efficiency, improve production scalability, and enable the company to meet increasing demand in both domestic and international markets. By integrating this facility with its existing manufacturing network, Fredun aims to reinforce its presence across pharmaceutical and nutraceutical segments while maintaining consistency in quality and compliance.
Commenting on the development, Managing Director FredunMedhora stated that the company is steadily strengthening its infrastructure in line with business growth. He noted that with emerging opportunities across core segments, the focus remains on building a scalable and resilient manufacturing foundation to support long-term objectives.
Fredun Pharmaceuticals has built a broad product portfolio that includes formulations for antihypertensive, antidiabetic, and antiretroviral therapies, along with a range of nutraceuticals, cosmeceuticals, and animal healthcare products. The company’s integrated approach allows it to cater to multiple healthcare needs, positioning it as a comprehensive solutions provider in the industry.
A significant portion of Fredun’s business comes from exports, with products reaching markets across Africa, Southeast Asia, the Commonwealth of Independent States (CIS), and Latin America. The company continues to focus on expanding its global footprint while maintaining regulatory standards and product quality.
For the financial year FY25, Fredun Pharmaceuticals reported total revenue of ₹456 crore, with an EBITDA of ₹55 crore and a profit after tax of ₹21 crore. These results reflect steady operational performance and provide a foundation for further expansion. With the addition of the Palghar facility, Fredun Pharmaceuticals aims to enhance its manufacturing capabilities and support its evolving business requirements, while continuing to serve growing healthcare demands across global markets.
